Liraglutide-related cholelithiasis.
Liraglutide is a glucagon-like peptide-1 analog and recently started to be using as an incretin-based treatment for diabetes mellitus. Liraglutide causes some adverse affects including nausea, vomiting, acute nasopharyngitis and acute pancreatitis. However, development of liraglutide-dependent cholelithiasis has not been reported in the literature. A 75-year-old female patient had been diagnosed with type 2 diabetes mellitus for 10 years and she has been treated by liraglutide for 6 months. The patient was admitted to the emergency service due to sudden onset of abdominal pain. After laboratory and imaging studies, she was diagnosed with acute cholecystitis and cholelithiasis. And then patient's oral intake was stopped, intravenous fluid and ceftriaxone 2 g/day were started. Furthermore, liraglutide treatment discontinued and ursodeoxycholic acid (UDCA) was started to treat cholelithiasis. During follow-up, abdominal pain completely relieved. Hepatobiliary ultrasonography in sixth month follow-up showed entirely regression of cholelithiasis. Any liraglutide-related cholelithiasis case has not been reported in the literature previously. Therefore, our case is the first case. Especially, elderly diabetic patients who are started to liraglutide treatment should be monitored closely for the formation of cholelithiasis. UDCA treatment would be an alternative prior to surgical treatment for liraglutide-related cholelithiasis.
Division of Endocrinology, Department of Internal Medicine, Faculty of Medicine, Gaziantep University, 27100, Sahinbey, Gaziantep, Turkey. drhkorkmaz@yahoo.com.tr.
Hakan
H
Korkmaz
Division of Endocrinology, Department of Internal Medicine, Faculty of Medicine, Gaziantep University, 27100, Sahinbey, Gaziantep, Turkey.
Mustafa
M
Araz
Department of Internal Medicine, Faculty of Medicine, Gaziantep University, 27100, Sahinbey, Gaziantep, Turkey.
Samet
S
Alkan
Division of Endocrinology, Department of Internal Medicine, Faculty of Medicine, Gaziantep University, 27100, Sahinbey, Gaziantep, Turkey.
Ersin
E
Akarsu
D000368:Aged; D002756:Cholagogues and Choleretics / Q000008:administration & dosage; D002769:Cholelithiasis / Q000139:chemically induced / Q000175:diagnosis / Q000503:physiopathology / Q000628:therapy; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D005260:Female; D052216:Glucagon-Like Peptide 1 / Q000031:analogs & derivatives; D006801:Humans; D007004:Hypoglycemic Agents / Q000008:administration & dosage / Q000009:adverse effects; D000069450:Liraglutide / Q000008:administration & dosage / Q000009:adverse effects; D016896:Treatment Outcome; D014580:Ursodeoxycholic Acid / Q000008:administration & dosage; D028761:Withholding Treatment
D002756:Cholagogues and Choleretics; D007004:Hypoglycemic Agents; D014580:Ursodeoxycholic Acid; D000069450:Liraglutide; D052216:Glucagon-Like Peptide 1
Cholelithiasis; Liraglutide; Ursodeoxycholic acid